Preclinical and clinical studies of patients with HER2 BC reports promising results upon merging chemotherapy with anti-HER2 monoclonal antibodies (trastuzumab and pertuzumab) (Piccart-Gebhart et al., 2005) and tyrosine kinase inhibitor (lapatinib and neratinib) based therapies (Cuzick et al., 2011). The gene discussed is ERBB2; the disease is breast cancer.